mRNA Vaccine Technology

mRNA vaccine technology, pioneered by Katalin Karikó and Drew Weissman through their modified nucleoside work, enabled the rapid development of COVID-19 vaccines by Pfizer-BioNTech and Moderna within 11 months—a speed record against any prior vaccine. These vaccines achieved 95% efficacy in clinical trials, outperforming #8's aspirin in precision by targeting the spike protein specifically. Karikó's discovery that pseudouridine reduced immune activation by 100-fold compared to unmodified mRNA was a critical data point, allowing safe delivery without severe inflammation. This technology is 40% faster to manufacture than the average vaccine, enabling billions of doses to be distributed globally. The 2023 Nobel Prize in Physiology or Medicine recognized this breakthrough, which outperforms #2's fullerenes in public health impact, potentially revolutionizing treatment for influenza and cancer.